296 related articles for article (PubMed ID: 31007119)
21. Pharmacist biosimilar survey reveals knowledge gaps.
Stevenson JG; McCabe D; McGrath M; McBride A
J Am Pharm Assoc (2003); 2023; 63(2):529-537.e7. PubMed ID: 36437154
[TBL] [Abstract][Full Text] [Related]
22. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
Van de Wiele VL; Kesselheim AS; Sarpatwari A
Health Aff (Millwood); 2021 Aug; 40(8):1198-1205. PubMed ID: 34339242
[TBL] [Abstract][Full Text] [Related]
23. Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey.
Chan A; Patel H; Siderov J; Bubalo J; Foreman E
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):11-21. PubMed ID: 32268832
[TBL] [Abstract][Full Text] [Related]
24. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
[No Abstract] [Full Text] [Related]
25. Dermatologists' Perspectives on Biosimilars.
Zameza PA; Kontzias C; Flanders K; Sonnenreich P; Feldman SR
J Drugs Dermatol; 2024 Apr; 23(4):277-280. PubMed ID: 38564397
[TBL] [Abstract][Full Text] [Related]
26. Are biosimilars patentable?
Rolfe D; Parker J; Morgan M
Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy.
Giavatto C; Mourani J; Fitzpatrick C; Hardin B; Skrtic A; Evans A; Sredzinski E; Trieu S; Setter AI; Kobiska L; Lopez-Medina AI
J Manag Care Spec Pharm; 2024 Feb; 30(2):175-182. PubMed ID: 38308629
[TBL] [Abstract][Full Text] [Related]
28. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
Cisek S; Choi D; Stubbings J; Bhat S
Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
[TBL] [Abstract][Full Text] [Related]
29. Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States.
Herndon K; Braithwaite J; Berry B; Bourget K
BioDrugs; 2021 Jan; 35(1):103-112. PubMed ID: 33400238
[TBL] [Abstract][Full Text] [Related]
30. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
[TBL] [Abstract][Full Text] [Related]
31. US rheumatologists' beliefs and knowledge about biosimilars: a survey.
Gibofsky A; McCabe D
Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388
[TBL] [Abstract][Full Text] [Related]
32. Following the Biosimilar Breadcrumbs: When Health Systems and Manufacturers Approach Forks in the Road.
Oskouei ST
J Manag Care Spec Pharm; 2017 Dec; 23(12):1245-1248. PubMed ID: 29172974
[TBL] [Abstract][Full Text] [Related]
33. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
34. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
[TBL] [Abstract][Full Text] [Related]
35. Harnessing the Biologics and Biosimilars Collective Intelligence Consortium to Evaluate Patterns of Care.
McMahill-Walraven CN; Kent DJ; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
J Manag Care Spec Pharm; 2019 Nov; 25(11):1156-1161. PubMed ID: 31397619
[TBL] [Abstract][Full Text] [Related]
36. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it.
Mehr SR
J Manag Care Spec Pharm; 2024 Jun; 30(6):600-603. PubMed ID: 38824633
[TBL] [Abstract][Full Text] [Related]
37. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
[TBL] [Abstract][Full Text] [Related]
38. Changes in PBM Business Practices in 2019: True Innovation or More of the Same?
Motheral BR; Fairman KA
J Manag Care Spec Pharm; 2020 Oct; 26(10):1325-1333. PubMed ID: 32869706
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
